33 Results for "

benign prostatic hyperplasia (BPH)

" in MedChemExpress (MCE) Product Catalog:
Products (33)

33 Results for "benign prostatic hyperplasia (BPH)" in MCE Product Catalog:

8
8 Publications Verification
Cat. No.: HY-B0371F
CAS No.: 63074-08-8
Terazosin hydrochloride is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .
loading...
    loading...
8
8 Publications Verification
Cat. No.: HY-B0371
CAS No.: 63590-64-7
Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .
loading...
    loading...
8
8 Publications Verification
Cat. No.: HY-B0371A
CAS No.: 70024-40-7
Terazosin hydrochloride dihydrate is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride dihydrate works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride dihydrate has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-13635
CAS No.: 98319-26-7
Purity:  99.97%
Synonyms: MK-906
Research Areas:  

Cancer

Finasteride (MK-906) is an orally active and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-B0192
CAS No.: 81403-80-7
Synonyms: SL 77499
Target:  

Adrenergic Receptor

Research Areas:  

Endocrinology

Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-B0192A
CAS No.: 81403-68-1
Synonyms: SL 77499-10
Target:  

Adrenergic Receptor

Research Areas:  

Endocrinology

Alfuzosin (SL 77499-10) hydrochloride is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin hydrochloride relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin hydrochloride can be used in study of benign prostatic hyperplasia (BPH) .
loading...
    loading...
Cat. No.: HY-115450
CAS No.: 856689-51-5
Purity:  99.43%
Target:  

LPL Receptor

Research Areas:  

Endocrinology Cancer

ONO-0300302 is an orally active and potent LPA1 (lysophosphatidic acid receptor 1) antagonist, with an IC50 of 0.086 μM. ONO-0300302 is a slow tight binding inhibitor, and its binding affinity increases with time, with Kd of 0.34 nM (37 °C, 2 h). ONO-0300302 can be used for benign prostatic hyperplasia (BPH) research .
loading...
    loading...
Cat. No.: HY-N8850
CAS No.: 83199-38-6
Angelol G, a coumarin, can be isolated from Campylotropis hirtella. Angelol G shows inhibitory activity for prostate specific antigen (PSA)IC50 value of 152.1μM. Angelol G can be used for the research of benign prostate hyperplasia (BPH) .
loading...
    loading...
Cat. No.: HY-P3501
CAS No.: 492447-54-8
Synonyms: NX-1207
Target:  

Apoptosis

Research Areas:  

Cancer

Fexapotide (NX-1207) induces apoptosis selectively, reducing prostate volume at a cellular level. Fexapotide can be used in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) research .
loading...
    loading...
Cat. No.: HY-12718
CAS No.: 613-67-2
Target:  

Adrenergic Receptor

Research Areas:  

Cardiovascular Disease

(±)-WB 4101 is a highly selective α1-adrenergic receptor antagonist. (±)-WB 4101 blocks norepinephrine-induced vascular smooth muscle contraction to exert antihypertensive and benign prostatic hyperplasia (BPH)-relieving effects. (±)-WB 4101 is promising for research of hypertension and BPH .
loading...
    loading...
Cat. No.: HY-B0371S
CAS No.: 1006718-20-2
Terazosin-d8 is deuterium labeled Terazosin. Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .
loading...
    loading...
Cat. No.: HY-13635A
CAS No.: 222989-99-3
Synonyms: MK-906 acetate
Target:  

5 alpha Reductase

Research Areas:  

Cancer

Finasteride (MK-906) acetate is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride acetate has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride acetate can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia .
loading...
    loading...
Cat. No.: HY-13635R
CAS No.: 98319-26-7
Synonyms: MK-906 (Standard)
Research Areas:  

Cancer

Finasteride (Standard) is the analytical standard of Finasteride. This product is intended for research and analytical applications. Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia .
loading...
    loading...
Cat. No.: HY-165478
CAS No.: 155651-56-2
Target:  

5 alpha Reductase

Research Areas:  

Endocrinology

FCE 28260 is an orally active 4-azacyclic 5α-reductase (5αR) inhibitor. FCE 28260 exhibits IC₅₀ values for human 5αR type 1 and 5αR type 2 of 36 and 3.3 nM, respectively, and for human and rat prostates with IC₅₀ values of 16 and 15 nM, respectively. FCE 28260 simultaneously blocks the production of dihydrotestosterone (DHT) in the prostate and peripheral tissues. FCE 28260 can significantly inhibit the induction of prostatic and seminal vesicle hyperplasia by testosterone (T) in rat models, without inhibiting the growth of the prostate in DHT implantation models. FCE 28260 can be used for the studies DHT-dependent diseases such as benign prostatic hyperplasia (BPH) .
loading...
    loading...
Cat. No.: HY-106614
CAS No.: 105149-00-6
Research Areas:  

Endocrinology

Osaterone acetate is an orally active steroid anti-androgen agent, mainly used for benign prostatic hyperplasia (BPH) in dogs. Osaterone acetate competitively antagonizes androgen receptor and inhibits 5α-reductase, reducing the concentration of dihydrotestosterone (DHT) while blocking the growth-stimulating effects of testosterone and DHT on prostate cells. Osaterone acetate can rapidly alleviate the symptoms of BPH in dogs without affecting the fertility of breeding dogs .
loading...
    loading...
Cat. No.: HY-106363
CAS No.: 103497-68-3
Synonyms: L 654066
Target:  

5 alpha Reductase

Research Areas:  

Others

MK-0963 is a steroidal 5α-reductase inhibitor. MK-0963 reduces serum dihydrotestosterone (DHT) concentrations in a dose-dependent manner. MK-0963 can be used for the study of dihydrotestosterone-related diseases such as benign prostate hyperplasia (BPH) .
loading...
    loading...
Cat. No.: HY-B0192AR
CAS No.: 81403-68-1
Synonyms: SL 77499-10 (Standard)
Research Areas:  

Endocrinology

Alfuzosin (hydrochloride) (Standard) is the analytical standard of Alfuzosin (hydrochloride). This product is intended for research and analytical applications. Alfuzosin (SL 77499-10) hydrochloride is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin hydrochloride relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin hydrochloride can be used in study of benign prostatic hyperplasia (BPH) .
loading...
    loading...
Cat. No.: HY-B0192AS
CAS No.: 1216383-97-9
Synonyms: SL 77499-10-d3
Alfuzosin-d3 hydrochloride is the deuterium labeled Alfuzosin hydrochloride. Alfuzosin hydrochloride is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).
loading...
    loading...
Cat. No.: HY-B0192AS1
CAS No.: 1276197-14-8
Synonyms: SL 77499-10-d7
Alfuzosin-d7 (hydrochloride) is the deuterium labeled Alfuzosin hydrochloride. Alfuzosin hydrochloride is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).
loading...
    loading...
Cat. No.: HY-P3501A
Synonyms: NX-1207 TFA
Target:  

Apoptosis

Research Areas:  

Cancer

Fexapotide (NX-1207) TFA induces apoptosis selectively, reducing prostate volume at a cellular level. Fexapotide can be used in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) research .
loading...
    loading...